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Nucleotide bindingIn its forward direction, transhydrogenase couples the reduction of NADP+ by NADH to the outward
translocation of protons across the membrane of bacteria and animal mitochondria. The enzyme has three
components: dI and dIII protrude from the membrane and dII spans the membrane. Hydride transfer takes
place between nucleotides bound to dI and dIII. Studies on the kinetics of a lag phase at the onset of a “cyclic
reaction” catalysed by complexes of the dI and dIII components of transhydrogenase from Rhodospirillum
rubrum, and on the kinetics of ﬂuorescence changes associated with nucleotide binding, reveal two features.
Firstly, the binding of NADP+ and NADPH to dIII is extremely slow, and is probably limited by the conversion
of the occluded to the open state of the complex. Secondly, dIII can also bind NAD+ and NADH. Extrapolating
to the intact enzyme this binding to the “wrong” site could lead to slip: proton translocation without change
in the nucleotide redox state, which would have important consequences for bacterial and mitochondrial
metabolism.ucleotide (oxidised form); dIII.
h Glu155 has been substituted
).
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Proton-translocating nicotinamide nucleotide transhydrogenase,
located in the cytoplasmic membrane of bacteria and the inner
mitochondrial membrane of animal cells, catalyses the reaction,
NADH + NADPþ + Hþout↔NAD
þ + NADPH + Hþin ð1Þ
Inward proton translocation through the enzyme, which can be
driven by the proton electrochemical gradient (Δp), is coupled to
transhydrogenation in its “forward” direction (left to right in the
equation). The resulting NADPH can be used in biosynthesis reac-
tions [1–3], and to reduce glutathione for protection against oxidative
damage [4–6]. There also appears to be a role for transhydrogenase in
glucose-dependent insulin secretion in the β-cells of mice [7,8], and the
enzyme has the capacity to regulate the rate of the tricarboxylic acid
cycle through interactions with the nucleotide substrates and products
of the isocitrate dehydogenases [9]. Uncertainties about the function of
the enzyme are not clariﬁed by the very patchy distribution of
transhydrogenase amongst species of both prokarotes and eukaryotes
revealed by genome sequences [10].
Transhydrogenase has three components: dI, which has the
binding site for NAD+/NADH, and dIII, which has the binding site
for NADP+/NADPH, protrude from the membrane (into the matrix ofmitochondria and the cytoplasm of bacteria), and dII spans the
membrane. High resolution structures in different nucleotide-bound
states are available for dI from Rhodospirillum rubrum [11,12] and
Escherichia coli [13], and for dIII from Bos taurus [14], Homo sapiens
[15] and R. rubrum [16]. There are also several X-ray structures of an
asymmetric dI2dIII1 complex of the R. rubrum enzyme [17–20] that
reveal features of the direct hydride transfer between bound
nucleotides. There is, as yet, no high resolution structure of dII.
Following early experiments on the steady-state kinetics of
transhydrogenase [21–23], the two classes of binding site on the
enzyme were thought to be speciﬁc for their respective nucleotides.
There is direct evidence for speciﬁc binding to isolated dI of NADH
relative to NADPH from ﬂuorescence [24] and NMR [25] experiments,
but tight nucleotide binding and slow rates of exchange have made
experiments with isolated dIII more difﬁcult. There has been a tacit
assumption of speciﬁcity because binding of a nucleotide into the
“wrong” site would result in enzyme slip: for example, inward proton
translocation, and hence dissipation of Δp, could take place without
any net oxidation or reduction of the nucleotides.
The activity of transhydrogenase is usually measured using
analogue nucleotides having distinctive absorbance spectra. Typically,
the reduction of acetyl pyridine adenine dinucleotide (AcPdAD+, an
analogue of NAD+) by NADPH is used to measure the rate of the
“reverse reaction” (right to left in Eq. (1)). Experimentswith AcPdAD+
also reveal an interesting set of partial reactions [22,26,27]. The “cyclic
reaction” is deﬁned [28] as the combined reduction of NADP+ by
NADH, and oxidation of NADPH by AcPdAD+, when both take place
without either the NADP+ or NADPH dissociating from their binding
site on dIII (see Fig. 1a); the net reaction is the reduction of AcPdAD+
by NADH, and is not accompanied by proton translocation [27,29,30].
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NADPH binding to, and dissociation from, dIII appear to be coupled by
long-distance conformational changes to proton translocation across
the membrane through dII [27,31,32]. In dI2dIII1 complexes, hydride
transfer between bound nucleotides [33,34], AcPdAD+ binding and
AcPdADH release, and NADH binding and NAD+ release, to/from dI
[35] are all fast processes but NADP+ andNADPHdissociation fromdIII
[36–39] is extremely slow. This combination results in rapid cyclic but
greatly depressed rates of forward and reverse transhydrogenation in
dI2dIII1 complexes.
A slow rate of what we shall here call an “aberrant cyclic reaction”
was observed in bacterial membrane fractions, and in puriﬁed
transhydrogenase of E. coli [27,28,40–42]. It was manifested as
AcPdAD+ reduction by NADH ostensibly in the absence of NADP+/
NADPH, and it was attributed to the binding of either AcPdAD+/Fig. 1. Partial reactions of transhydrogenase. (a) The cyclic reaction (only NAD+, NADH,
AcPdAD+ and AcPdADH occupy the dI site, and only NADP+ and NADPH occupy the dIII
site). (b) An aberrant cyclic reaction (with NAD+ and NADH occupying the dIII site).
The schemes apply to dI2dIII1 complexes, and in a limited way, to the intact enzyme
(see text). The dotted lines indicate interactions between dI and dIII, and between the
protein components and bound nucleotides. The dotted arrows show the two hydride-
transfer steps in the cyclic reaction, and in the aberrant cyclic reaction. Only one of the
two dI subunits is depicted.AcPdADH or NAD+/NADH into the wrong site on dIII [41,42]. Thus,
either the AcPdAD+/AcPdADH or the NAD+/NADH, whilst remaining
bound to dIII, are alternately reduced by NADH, and oxidised by
AcPdAD+, bound to dI. The form of aberrant cyclic in which NAD+/
NADH operates within the dIII site is shown in Fig. 1b. Typically, the
aberrant cyclic reaction in intact transhydrogenase occurs at only a
few percent of the rate of the cyclic reaction [28]. However, in an
interesting series of experiments conducted by Pedersen et al. [43],
tightly bound NADP+ and NADPH were removed from isolated E. coli
dIII by treatment with alkaline phosphatase (see below), and the
resulting “apo-dIII” was used to produce hybrid complexes with R.
rubrum dI (see also [39]). These complexes were found to catalyse
remarkably rapid rates of the aberrant cyclic reaction, and thus raised
questions about nucleotide speciﬁcity of the dIII site in transhydro-
genase. In the current paper we repeat the experiments of Pedersen et
al. but using dI2dIII1 complexes in which both components were
derived from the R. rubrum enzyme. Equivalent results were obtained,
although our analysis of the reaction kinetics establishes that NAD+/
NADH, but not AcPdAD+/AcPdADH, can bind to the dIII site and
support the aberrant cyclic reaction. Moreover, the experimental
protocol enabled us to show that the binding of nucleotide (whether
NADP+ or NADH) into the dIII site of dI2dIII1 complexes is extremely
slow.We have also isolated an R165Amutant of the dIII component of
R. rubrum transhydrogenase. X-ray structures show that, in wild-type
dIII, the guanidinium sidechain of Arg165 forms two hydrogen bonds
to the 2′-phosphate of NADP+ and NADPH [19]. Mutation of the
equivalent residue (Arg425) and the adjacent Lys424 in E. coli dIII led
to weaker binding of NADP+/NADPH [44,45]. In the R165Amutant of R.
rubrum dIII, we also ﬁnd that NADP+ binds more weakly, making it
easier experimentally to prepare the apo-form of the protein without
theneed for alkalinephosphatase; againweﬁndevidenceof anaberrant
cyclic reaction in which NADH but not AcPdAD+ binds into the wrong
site. Support for the low speciﬁcity, and for very slow binding of
nucleotides, into the dIII site of dI2dIII1 complexes constructed using
either wild-type apo-dIII or apo-dIII.R165A is also provided by
ﬂuorescence experiments. The physiological signiﬁcance of NADH
binding into the wrong site of transhydrogenase will be discussed.
2. Materials and methods
Recombinant dI, dIII and the mutant, dIII.E155W, of R. rubrum
transhydrogenase were expressed from plasmids pCD1 [24], pNIC2
[46] and pJDV1 [47], respectively, in appropriate strains of E. coli after
growth in LB medium at 37 °C and induction with isopropyl
thiogalactoside. The proteins were puriﬁed from harvested cells by
column chromatography, and stored as described in the earlier
reports (and see [48]). Protein concentrations were determined using
the microtannin assay [49]. The NADP+ content of some dIII
preparations was assayed as described [36,50]. In attempts to lower
the NADP+ content of dIII, puriﬁed protein (3.0 ml) was passed twice
through two sequentially mounted 5 ml HiTrap desalting columns
(GE Healthcare) pre-equilibrated with 20 mM Tris–HCl, pH 8.0. NADP+
was more thoroughly removed from dIII by the procedure described
for the E. coli protein [43]. R. rubrum dIII was ﬁrst dialysed against
20 mM CHES-KOH, pH 9.0 for 16 h at 4 °C. Aliquots (typically 200 μl of
20 μM protein) were then incubated with calf-intestinal alkaline
phosphatase (40 U) from New England Biolabs for 10 min at 37 °C,
plunged into ice, and used within 30 min. To conﬁrm that this
procedure led to removal of NADP+, the protein aliquots (before and
after phosphatase treatment) were added to 1.8 ml 20 mMMOPS-KOH,
pH 7.0, 5 mM MgCl2, 2 mM isocitrate, and the ﬂuorescence change
resulting from the addition of 1 U of porcine NADP+-linked isocitrate
dehydrogenase (Sigma Life Science) was recorded using 340 nm
excitation and 460 nm emission on a PTI Quantamaster ﬂuorimeter.
To conﬁrm the generation of NAD+ from alkaline phosphatase
treatment of dIII, similar protein aliquots were added to 1.8 ml
Table 1
NADP+ content of wild-type dIII and dIII.R165A from R. rubrum transhydrogenase.
Protein NADP+ before GFa
(mol NADP+ mol−1 protein)b
NADP+ after GFa
(mol NADP+ mol−1 protein)
Wild-type dIII 0.71, 0.79, 0.73 0.75, 0.78, 0.78
dIII.R165A 0.28, 0.35, 0.12 0.00, 0.01, 0.04
a GF=gel ﬁltration, see Materials and methods.
b The NADP+ content was determined as described in Materials and methods. Values
are shown for three separate protein preparations each of wild-type and mutant dIII.
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ﬂuorescence changes upon addition of 10 U of yeast alcohol dehydro-
genase (Sigma Life Science) were recorded.
Plasmid pCD1 was subjected to site-directed mutagenesis using
the Stratagene Quikchange kit and DNA primers from AltaBiosciences
to give the plasmid pLH4 harbouring the gene encoding dI.W72F.
This plasmid was used to transform cells of E. coli C600, and the
mutant dI protein was expressed and puriﬁed as described for wild-
type dI (see above).
Plasmid pNIC2 was subjected to site-directed mutagenesis by
Yorkshire Biosciences Ltd. to give the construct, pLH1, harbouring the
gene encoding dIII.R165A. This plasmid was used to transform cells of
E. coli BL21(DE3), and the mutant protein was expressed as described
for wild-type dIII (see above). However, unlike wild-type dIII the
mutant protein was predominantly found in the inclusion-body
fraction after cell breakage, and a new procedure was therefore
devised for puriﬁcation. Cells were harvested from 3.2 l of culture, and
washed and sonicated in 50 mM Tris–HCl, pH 8.0, 1.0 mM EDTA,
100 μM NADP+, 500 μM phenylmethanesulfonyl ﬂuoride, as de-
scribed for the wild-type protein (see above). The resulting extract
was centrifuged at 150,000×g for 1 h, and the pellet was resuspended
in 80 ml 20 mM Tris–HCl, pH 8.0, 6.0 M guanidine-HCl, 4 μM NADP+,
and incubated on ice for 30 min. After subsequent centrifugation at
90,000×g, the supernatant was diluted 35-fold in 20 mMTris–HCl, pH
8.0, 6.0 M guanidine-HCl, 4 μM NADP+, and stored at −20 °C.
Approximately 40 ml of the stored material was thawed on ice and
dialysed against 4 l 30 mMHEPES-KOH, pH 8.0, 10 μMNADP+, 15% (v/
v) glycerol at 4 °C for 1 h. The dialysed material was concentrated by
loading on to a 5 ml QHP HiTrap column (GE Healthcare) pre-
equilibrated with 20 mM Tris–HCl, pH 8.0, 4 μM NADP+ and eluting
with 20 mM Tris–HCl, pH 8.0, 4 μMNADP+, 2.0 M NaCl. Analysis of this
material by SDS-PAGE established that the dIII.R165A proteinwas N95%
pure. NADP+ was removed from the puriﬁed protein (3.0 ml) by
passing twice through two sequentially mounted 5 ml HiTrap desalting
columns pre-equilibrated with 20 mM Tris–HCl, pH 8.0.
Plasmid pLH1 was subjected to another round of site-directed
mutagenesis using the Stratagene Quikchange kit and AltaBiosciences
DNA primers to give the plasmid pLH2 harbouring the gene encoding
the double mutant, dIII.E155W.R165A. This plasmid was used to
transform cells of E. coli BL21(DE3), and the double-mutant protein
was expressed and puriﬁed as described above for dIII.R165A.
AcPdAd+ reduction was measured from the absorbance change at
375 nm recorded on a Shimadzu UV-2401 spectrophotometer with an
absorbance coefﬁcient of 6.1 mM−1 cm−1. The standard assay for cyclic
transhydrogenation contained 50 mMMOPS-KOH, pH 7.2, 50 mM KCl,
2 mM MgCl2, 100 μM NADH, 1.0 μM dI and 30 nM dIII (either in its
NADP+-bound state or supplemented with 100 μM NADP+) at 25 °C;
after 2 min pre-incubation, the reaction was initiated by addition of
200 μM AcPdAD+. The standard assay for reverse transhydrogenation
was performed in the same way but using 200 μM NADPH instead of
NADH, 5.0 μM dI and 150 nM dIII without added NADP+. Trp-
ﬂuorescence changes associated with nucleotide binding were
recorded on a PTI Quantamaster ﬂuorimeter.
3. Results
3.1. Nucleotide binding to the apo-dIII component of R. rubrum
transhydrogenase
The isolated dIII components of R. rubrum [36], E. coli [38,39] and
human [51] transhydrogenase have a high afﬁnity for NADP+/NADPH
at their single nucleotide-binding sites; an interpretation of published
data [52] indicates that the same is true for bovine dIII [36]. Buffer
solutions used in the puriﬁcation procedure for R. rubrum dIII contain
4 μMNADP+ tomaintain the site occupancy [53]. Despite its relatively
low molecular weight (765 Da), we found NADP+ to be extremelyslow to permeate through either Visking or Spectra/Por dialysis
membrane (fromMedicell), both of which have a reported 12–14 kDa
cut-off. We therefore used gel-ﬁltration chromatography in an
attempt to remove NADP+ from the dIII protein. After two passages
down the column (see Materials and methods), the NADP+ content
was still high, at ~0.8 mol nucleotide mol−1 dIII (Table 1). Further
NADP+ was therefore removed by treatment with alkaline phospha-
tase, as described for E. coli dIII [43]. Although the degree of
dissociation of NADP+ from dIII is slight, the high concentration of
alkaline phosphatase used in the treatment ensures gradual cleavage
of the 2′-phosphate from the nucleotide released into solution, and
eventual complete conversion to NAD+, which binds only very weakly
to the protein (see below). To conﬁrm this reasoning, nucleotide
ﬂuorescence changes were recorded during addition of iso-citrate
(IC) and NADP+-dependent iso-citrate dehydrogenase (ICDH) to
solutions of the R. rubrum dIII (see Materials and methods and [43]).
Before treatment of the dIII with alkaline phosphatase, slow reduction
of NADP+ by the IC/ICDH was evident from the ﬂuorescence increase
(data not shown); after treatment, the ﬂuorescence change was
decreased by N90%. The conversion of bound NADP+ to NAD+ was
checked bymeasuring theﬂuorescence change upon addition of NAD+-
dependent alcohol dehydrogenase to the phosphatase-treated samples
of dIII (see Materials and methods).
In agreement with earlier results [36], reverse transhydrogenation
catalysed by R. rubrum dI2dIII1 complexes formed from dI and
untreated dIII was extremely slow: the rate of AcPdAD+ reduction
by NADPH in current experiments was approx 1.4 mol AcPdAD+
reduced mol−1 dIII min−1. Relative to the much faster reverse
reaction in the intact enzyme (N1000 fold), that in dI2dIII1 complexes
is heavily limited by very slow release of product NADP+ from dIII
[36]. Also in agreement with the previous results, cyclic transhydro-
genation in dI2dIII1 complexes prepared from dIII untreated with
phosphatase was very fast—it takes place by way of the tightly bound
NADP+ on dIII (Fig. 1a): the rate of AcPdAD+ reduction by NADH in
current preparations in standard assays (see Materials and methods)
was 2710±570 mol AcPdAD+ reducedmol−1 dIII min−1 (mean value
from four preparations each of dI and dIII).
The low level of bound NADP+ and NADPH in the phosphatase-
treated dIII enables us to measure separately the rates of cyclic and
aberrant cyclic transhydrogenation in dI2dIII1 complexes. In the
experiment shown in Fig. 2a, 30 nM phosphatase-treated dIII was
ﬁrst mixed with excess dI (1 μM) to ensure that essentially all the
former was in complex (Kd≤60 nM [37]), and the proteins were then
incubated with NADH for 2 min before addition of AcPdAD+.
Reduction of the AcPdAD+ began promptly at a rapid rate
(2280 mol AcPdAD+ reduced mol−1 dIII min−1) and continued
almost linearly for ~30 s before it began to decline through substrate
depletion and product accumulation. As was concluded in equivalent
experiments with the hybrid E. coli/R. rubrum dI2dIII1 complexes [43],
this AcPdAD+ reduction can be attributed, in the absence of NADP+/
NADPH, to an aberrant cyclic reaction with either NAD+/NADH
(Fig. 1b) or AcPdAD+/AcPdAdH on the dIII (see also [41,42]). In the
experiment shown in Fig. 2d, a similar mixture of dI and phosphatase-
treated dIII was incubatedwith NADP+ and AcPdAD+ for 2 min before
addition of NADH. Again rapid AcPdAD+ reduction then began
promptly (2360 mol AcPdAD+ reduced mol−1 dIII min−1) and
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Fig. 2. AcPdAD+ reduction by dI2dIII1 complexes from R. rubrum transhydrogenase. AcPdAD+ reduction was measured from the absorbance change at 375 nm. Each assay contained
50 mMMOPS-KOH, pH 7.2, 50 mMKCl and 2 mMMgCl2. T=25 °C. Nucleotides and transhydrogenase protein components, present at the start of the experiment, are shown behind
the curly brackets; recording began approx 2 min after their mixing by addition of either nucleotide or protein as indicated by arrows. For clarity, disturbances caused by the mixing
procedure are replaced by the dashed lines; the instantaneous change upon mixing is due to the absorbance of added nucleotide and protein. Where shown, dI was added to give
1.0 μM, and dIII, 30 nM. The dIII used in all these experiments was the wild-type form pre-treated with alkaline phosphatase, as described inMaterials andmethods.Where shown in
(a), (b) and (d), the nucleotide additions were: NADH, 200 μM; AcPdAD+, 200 μM; and NADP+, 200 μM.Where shown in (c) and (e), they were: NADH, 100 μM; AcPdAD+, 200 μM;
and NADP+, 100 μM.
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Fig. 3. Rates of AcPdAD+ reduction by dI2dIII1 complexes from R. rubrum transhy-
drogenase during the lag phase at the onset of cylic and aberrant cyclic transhy-
drogenation. The apo-form of wild-type dIII was prepared by phosphatase treatment,
and of dIII.R165A, by two passages down a gel-ﬁltration chromatography column (see
Materials and methods). Rates of AcPdAD+ reduction were measured from experi-
ments: ●, with complexes of wild-type dI and wild-type apo-dIII, using the protocol
shown in Fig. 2a; ○, from similar experiments but using complexes formed from wild-
type dI and apo-dIII.R165A;▲, from experiments using wild-type dI and wild-type apo-
dIII, and initiating the reaction with a mixture of 200 μMNADH plus 200 μMNADP+; Δ,
from similar experiments using wild-type dI and apo-dIII.R165A. Rates were calculated
from tangents to the absorbance change at 375 nm, and were plotted as a function of
time after initiating the reaction. Results of duplicate experiments from each
experimental condition are presented to illustrate scatter on the data.
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have arisen from a combination of cyclic and aberrant cyclic
transhydrogenation depending on whether NADP+/NADPH occupied
the dIII site (cyclic) or either NAD+/NADH or AcPdAD+/AcPdADH
(aberrant cyclic).
A study of the kinetics of AcPdAD+ reduction helps to identify the
nucleotides bound to dIII. Firstly, we investigated the aberrant cyclic
reaction.When the experiment described in Fig. 2a was repeated with
a shorter exposure of the dI2dIII1 complexes to NADH (~30 s) before
adding the AcPdAD+, the reaction began with a slight lag, and at even
shorter exposures, the duration of the lag phase increased (data not
shown). This mixing protocol was too awkward for reliable
measurement but the experiment suggests that a period of incubation
of the protein with NADH is needed before the full rate of the aberrant
cyclic reaction is reached. In support of this, the lag phase was
pronouncedwhen the order of nucleotide additionswas reversed, and
the dI2dIII1 complexes were pre-incubated with AcPdAD+ before
initiating the reaction with NADH (Fig. 2b). The duration of the lag
phase in this experimental format (arbitrarily deﬁned as the time
taken for the reaction to reach half its maximal rate—see also Fig. 3)
was 15–20 s, and was independent of the time of exposure (5 to 60 s)
to the AcPdAD+ (data not shown). In a different protocol (Fig. 2c), dI
was pre-incubated with NADH and AcPdAD+, and the reaction was
then initiated by addition of dIII. Again the lag was pronounced; the
time taken for the reaction to reach half its maximal rate was 15–20 s,
and the lag-phase duration did not depend on the time of pre-
incubation of the dI with NADH and AcPdAD+. These results suggest
that the lag phase is the result of a slow interaction between NADH
and dIII. Note that in dI2dIII1 complexes formed from dIII untreated
with phosphatase (not shown), there was no lag in equivalent
experiments to those shown in Fig. 2b and c because the dIII site was
already loaded with NADP+ (thus leading to a prompt cyclic reaction,
Fig. 1a). Stopped-ﬂow experiments have established that R. rubrum dI
and dIII very rapidly associate to generate dI2dIII1 complexes [53], and
that NAD+, NADH, AcPdAD+, AcPdADH binding to, and release from,
dI are all very fast relative to the duration of the lag phase seen in thecurrent experiments [35]. The lag phase must arise from a slow rate of
binding of NADH to the dIII. Once bound, the NADH on dIII is rapidly
oxidised by AcPdAD+ on dI to give NAD+which remains bound to the
dIII. This NAD+ is then re-reduced by NADH on dI in an aberrant cyclic
reaction, as shown in Fig. 1b. Note that NADH and NAD+ remain bound
in the dIII site during the cycle, and that NAD+, NADH, AcPdAD+ and
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Fig. 4. The dependence of the rate of AcPdAD+ reduction upon NADH concentration
during aberrant cyclic, and upon NADP+ concentration, during cyclic transhydrogena-
tion. Experiments were performed with the apo-form of either wild-type dIII, prepared
by phosphatase treatment, or dIII.R165A, prepared by two passages down a gel-
ﬁltration chromatography column (see Materials and methods). The buffer and protein
concentrations were as described in Fig. 2. ● (and solid lines), complexes formed from
wild-type dI and wild-type apo-dIII; ▲ (and dashed lines), complexes formed from
wild-type dI and apo-dIII.R165A. Top panel: the buffer, together with dI and the
appropriate dIII, were incubated with NADH (at the concentration shown) for 5 min,
and the aberrant cyclic reaction was then initiated with 200 μM AcPdAD+. Bottom
panel: the buffer, together with dI and the appropriate dIII, were incubated with
200 μM AcPdAD+ and NADP+ (at the concentration shown) for 5 min and the reaction
was then initiated with 100 μM NADH. Rates were measured immediately after
disturbances from the mixing had subsided.
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contrast toNADH,AcPdAD+ is unable tobind todIII andparticipate in an
aberrant cyclic reaction: if AcPdAD+ had bound to dIII during the 60 s
incubation period in the experiment of Fig. 2b, then the reaction would
have begun without a lag after the addition of NADH. Thus, the
participation of AcPdAD+ in the experiments shown in Fig. 2 is only
through its binding to dI.
Further study of the AcPdAD+-reduction kinetics showed that
the binding of NADP+ to apo-dIII prior to a cyclic reaction is also a
slow process. When the experiment of Fig. 2d (see above) was
repeated with a shorter exposure (~30 s) of the dI2dIII1 complexes to
NADP+ and AcPdAD+ before adding NADH, the reaction began with
a slight lag. At even shorter exposures, the duration of the lag phase
increased but this mixing protocol was again too awkward for
reliable measurement. However, in a modiﬁed protocol (Fig. 2e), dI
was preincubated with NADP+, AcPdAD+ and NADH, and reaction
then initiated by addition of phosphatase-treated dIII. In this case
the lag phase at the onset of the reaction was pronounced; the time
taken for the reaction to reach half its maximal rate was again 15–
20 s. It is concluded that the lag in this experiment arises from slow
binding of NADP+ to the dIII before the onset of cyclic transhy-
drogenation (Fig. 1a).
The steady-state rate of the aberrant cyclic reaction was similar to
that of the cyclic reaction (compare the experiments of Fig. 2a and d,
respectively). That is, the rate of AcPdAD+ reduction was similar
when NAD+/NADH (“wrong” nucleotides, Fig. 1b) as distinct from
NADP+/NADPH (“right” nucleotides, Fig. 1a) occupied the dIII site.
We have used the analysis developed above to determine the
kinetics of binding of the wrong and right nucleotides into the dIII site.
In the ﬁrst set of experiments, a protocol similar to that shown in
Fig. 2b for aberrant cyclic transhydrogenation was adopted. The
instantaneous rate of AcPdAD+ reduction (the ﬁrst derivative of the
absorbance change) during the lag phase was plotted against time in
Fig. 3. Since the rate of NADH binding is slow, and the rates of other
component reactions are fast (see above), the rate of AcPdAD+
reduction during the lag phase is proportional to the degree of
occupancy of the dIII site. The plots therefore show the ﬁlling of the
dIII site with NADH. In a second set of experiments, the protocol was
modiﬁed by adding NADP+ simultaneously with the NADH; again the
instantaneous rate of AcPdAD+ reduction during the lag phase was
plotted against time (Fig. 3). Here, the NADH and NADP+ compete for
binding to dIII to produce a population of complexes catalysing
aberrant cyclic, and a population catalysing cyclic transhydrogena-
tion. Fig. 3 plots were normalised to the same maximum rate (at the
end of the lag phase), and show that representative experiments from
the two sets gave similar binding kinetics.
The protocols of the experiments used in Fig. 2 were also
extended to compare the concentration dependences for NADH and
NADP+. The dependence of the rate of the aberrant cyclic reaction on
the NADH concentration, and of the rate of the cyclic reaction on the
NADP+ concentration, are shown in Fig. 4. In both sets of
experiments, time was given to allow the NADH and the NADP+ to
reach binding equilibrium with the dIII site before initiating the
reaction. The nucleotide concentration needed to reach the respec-
tive half-maximal rate was 40 μM for NADH, and 5 μM for NADP+.
The former value is probably dominated by the relatively low
binding afﬁnity of NADH for dI (Kd≈20 μM) [37]; the latter might
partly reﬂect the higher afﬁnity of the NADP+ for dIII. However,
analyses of these data are complicated by a small contribution to the
intial rate of the cyclic reaction from the aberrant cyclic reaction at
low concentrations of NADP+ even during the ﬁrst few seconds after
adding the NADH, and also from the kinetic complexities of these
reactions, including the substrate inhibition arising because NADH
and AcPdAD+ both compete for the same binding site on dI—observe
the decrease in rate at high concentrations of NADH in the top panel
of Fig. 4, and see [54].3.2. Nucleotide binding to the R165A mutant of R. rubrum dIII
Although wild-type dIII was mostly expressed in the soluble
fraction of host cells (e.g. [36]), the dIII.R165A mutant was expressed
predominantly in inclusion bodies. A new procedure was therefore
devised to purify dIII.R165A involving solubilisation of the protein
followed by refolding (see Materials and methods). Control experi-
ments established that wild-type dIII recovered full activity when
subjected to the same procedure (results not shown). Table 1 reveals
that in contrast to wild-type dIII, bound NADP+ originating from
preparation buffers was almost completely removed from dIII.R165A
by two steps of gel-ﬁltration chromatography (see Materials and
methods)—this therefore provides a simple procedure for preparing
apo-dIII.R165A; phosphatase treatment of the mutant protein is not
required. The rate of reverse transhydrogenation catalysed by
complexes of dI and dIII.R165A in the standard assay conditions
(see Materials and methods) was approx 13 mol AcPdAD+ reduced
mol−1 dIII min−1—about 9-fold greater than the rate obtained with
wild-type protein. An increase in the rate of reverse transhydrogenation
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with R. rubrum dI [45]. The increase is attributable to the enhanced rate
of NADP+ release from the mutant proteins. Note that, in complexes of
R. rubrum dI and dIII.R165A, the rate of reverse transhydrogenation is
still about 100-fold lower than the rate of the cyclic reaction (see
below): evidently, NADP+ release from dIII.R165A still heavily restricts
the reverse reaction.
Experiments were performed using protocols identical to those
described in Fig. 2a and d but with mixtures of dI and apo-dIII.R165A.
The steady-state rate of the aberrant cyclic reaction (protocol of Fig. 2a)
was about 20% lower, and of the cyclic reaction (protocol of Fig. 2d),
about 35% lower, than those observed with the mixtures of dI and
phosphatase-treated wild-type dIII (data not shown). Importantly
however, the absence of a lag at the onset of AcPdAD+ reduction in
equivalent experiments to those described in Fig. 2a and d, and the
presence of a lag in equivalent experiments to Fig. 2b, c ande,were also a
feature of the complexes prepared fromdI and apo-dIII.R165A (data not
shown). By the same reasoning, the lags are a consequence of slow
NADH binding to apo-dIII.R165A at the onset of the aberrant cyclic
reaction, and of slow NADP+ binding to apo-dIII.R165A at the onset of
the cyclic reaction. The lag kinetics, representing the ﬁlling of the site
withnucleotide (see above),were similar forNADHandNADP+binding
to dI complexes with apo-dIII, and with apo-dIII.R165A (Fig. 3).
The dependence of the rate of the aberrant cyclic reaction on the
NADH concentration, and of the rate of the cyclic reaction on the
NADP+ concentration, inmixtures of dI and apo-dIII.R165A are shown
in Fig. 4. The NADH proﬁle is not signiﬁcantly different from that
determined with complexes of dI and apo-dIII but the NADP+ proﬁle
shows that a higher concentration of the nucleotide is needed to
achieve the half-maximal rate than with the wild-type protein
complex (~30 μM). Although there are difﬁculties in the analysis of
these experiments (see above), the results indicate that the R165A
mutation may have a greater effect on the dIII afﬁnity for NADP+ than
for NADH, which is consistent with the speciﬁc interaction of Arg165
and the 2′-phosphate group of the bound nucleotide seen in X-ray
structures [19].
Note that the experiments with apo-dIII.R165A described above
were all performed at similar protein concentrations to thosewithwild-
type apo-dIII. Separate experiments using a similar protocol to that in
Fig. 2d, were undertaken to determine the dependence of the rate of
cyclic transhydrogenation on dI concentration at ﬁxed dIII (30 nM). The
concentration of dI required for ahalf-maximal rate of the cyclic reaction
was ~40 nMwithwild-type apo-dIII and ~100 nMwith apo-dIII.R165A.
This suggests a slightly lower afﬁnity of dI for the mutant but conﬁrms
that the experiments described above and below were all performed
with dIII essentially in its fully complexed form with dI.
3.3. Nucleotide binding to dI2dIII1 complexes determined by protein
ﬂuorescence
In the dIII.E155W mutant of R. rubrum transhydrogenase, the Glu
residue at position 155 is substituted by a Trp, which becomes the
only Trp in the protein. The mutant protein has very similar catalytic
properties to those of wild-type dIII but ﬂuorescence from Trp155
provides a valuable probe with which to monitor nucleotide binding;
emission is more intense when NADP+ is bound to dIII than when
NADPH is bound [34,35,37,47,55] and see [38,39]. In the present work,
we have used a dIII.E155W.R165A double mutant, and phosphatase-
treated dIII.E155W, to examine nucleotide binding to the apo forms of
the protein using ﬂuorescence. The rate of cyclic transhydrogenation
in complexes formed from dI and dIII.E155W.R165A (1770±130 mol
mol−1 min−1, the mean for three preparations) was similar to that
formed from dI and dIII.R165A (1750±380 mol mol−1 min−1 for
three preparations) in the standard assay—as expected from earlier
results with the wild-type protein, the introduction of the E155W
mutation does not signiﬁcantly affect catalytic activity.We have also isolated a mutant of dI (designated dI.W72F) in
which Trp72, the only Trp in dI, was substituted with a Phe. The
mutant dI protein was fully active in complex with wild-type dIII, the
preparation having a cyclic transhydrogenation rate of 3170 mol
AcPdAD+ reduced mol−1 dIII min−1 in standard assay conditions. The
intense and unusually short-wavelength emission at 308 nm of wild-
type dI, studied in depth [56,57], was decreased 8-fold in dI.W72F
with 275 nm excitation, and 26-fold with 290 nm excitation (not
shown); the residual ﬂuorescence (λmax=303 nm, probably due to
Tyr emission) was not changed upon NADH binding (compare with
wild-type dI ﬂuorescence [24])—data not shown. The availability of dI.
W72F has therefore enabled us to investigate ﬂuorescence changes
(from the now single Trp155) that result from nucleotide binding to
the dIII component of generic dI2dIII1 complexes without any
interference from ﬂuorescence changes due to Trp72 in the dI.
Fig. 5 summarises results from two sets of experiments: complexes
were generated from dI.W72F and either apo-dIII.E155W (nucleotide
removed by phosphatase-treatment) or apo-dIII.E155W.R165A (nu-
cleotide removed by gel ﬁltration). The Trp155 ﬂuorescence was then
measured during addition of various nucleotides, all at 20 μM. In each
case, nucleotide addition led to a prompt artefactual decrease in
ﬂuorescence due to an “inner-ﬁltering” effect (the absorption of
excitation and/or emission light by the nucleotide). Following the
inner-ﬁltering effect, NADP+ gave rise to a slow increase in
ﬂuorescence (Fig. 5b and e), and the reduced nucleotides, NADPH
(Fig. 5a and d) and NADH (Fig. 5c and f), a slow decrease in
ﬂuorescence. These ﬂuorescence changes signify nucleotide binding
to the dIII component of the complex. Analysis of replicate experi-
ments established that NAD+ addition led to a small increase (~1%) in
ﬂuorescence, but that AcPdAD+ addition did not cause any signiﬁcant
ﬂuorescence change. Although the ﬂuorescence changes produced by
the nucleotides were small (b10% of the total emission), and subject
to rather large error on the long time scale of the experiments, the
kinetics of the changes were approximately the same for oxidised and
for reduced nucleotides, and for both types of protein complex.
Analysis of several replicate experiments indicated a half time for the
changes of approximately 20 s—similar to the half-time for the
increase in the rate of cylic and aberrrant cyclic transhydrogenation
attributed to NADP+ and NADH binding, respectively, during the lag
phase in Fig. 3. Experiments at different nucleotide concentrations
with dI2dIII.E155W.R165A indicated that NADPH bound tightly to the
dIII component of the complex (Kd≈0.1 μM), that NADP+ and NADH
boundwith Kd values in the region of 5 μM, and that NAD+ bound only
weakly.
If the binding of nucleotide to dIII were a simple, second-order
reaction, then the initial rate of the ﬂuorescence change (following the
inner-ﬁltering effect) would be directly proportional to the nucleotide
concentration. However, at least with NADP+, NADPH and NADH, in
dI2dIII.E155W.R165A complexes, this was not the case: increase in
nucleotide concentration led to a less than proportionate increase in
initial rate. Because of its high afﬁnity, this was most readily seen with
NADPH. Thus, above 1 μMnucleotide,where the binding siteswere fully
occupied at equilibrium, and below 50 μMnucleotide, where the inner-
ﬁltering effect was still managably small, the initial rate of the
ﬂuorescence change was independent of nucleotide concentration
(data not shown). The experiments reveal that the nucleotide-binding
reaction is not a simple second-order process but that binding is likely to
be associated with a protein conformational change.
In earlier work (with complexes containing wild-type dI) it was
shown that exchange of NADP+ for NADPH led to a decrease in dIII.
E155W ﬂuorescence, and exchange of NADPH for NADP+ to an increase
inﬂuorescence [37,47,55] and see [38]. The change inﬂuorescencecould
have been explained by resonance energy transfer from Trp155 to the
NADPH. However, the current ﬁnding that NADP+ itself enhances the
ﬂuorescence of apo-dIII indicates that local changes in the environment
around Trp155 resulting from nucleotide binding, rather than energy
(dI.W72F)2 dIII.E155W (dI.W72F)2 dIII.E155W.R165A
NADPH NADPH
NADP + NADP
+
10% ΔF 
NADH
NADH
50 s
a
b
c
d
e
f
Fig. 5. The ﬂuorescence change of Trp155 in the dIII component of dI2dIII1 complexes from R. rubrum transhydrogenase caused by addition of nucleotides. Experiments on the left
were performed with apo-dIII.E155W, prepared by phosphatase treatment, and those on the right with apo-dIII.E155W.R165A, prepared by two passages down a gel-ﬁltration
chromatography column (seeMaterials andmethods). The dIII proteins (400 nM), together with dI.W72F (800 nM), were incubated in 20 mMMOPS-KOH, pH 7.0, for approximately
5 min to record a baseline before addition of nucleotides (all 20 μM) at the arrows. The initial prompt ﬂuorescence decrease in all experiments is the result of the inner-ﬁltering effect
of the nucleotide. Excitation, 280 nm; emission, 340 nm; half band widths, 4 nm; T=25 °C.
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Trp155 environment caused by reduced nucleotides are different from
those caused by oxidised nucleotides.
4. Discussion
Studies on high-resolution structures and the reaction kinetics of
transhydrogenase have provided a framework for understanding the
mechanism of action of the enzyme [31,32] (but see [58] for some
unresolved considerations). Central to the mechanism is that, in the
forward direction (Eq. (1)), inward proton translocation through dII
drives the protein through an “open” state, in which dIII releases the
product NADPH and re-binds fresh NADP+, and an “occluded” state, in
which the hydride-transfer step takes place. The dI component can
bind and release nucleotides in both states. Isolated dI2dIII1
complexes, in the absence of the membrane-spanning dII, behave as
though they are locked in the occluded state [31]. Thus, they display
very rapid rates of hydride transfer between bound nucleotides
[33,34] and, as measured in exchange reactions [47], extremely slow
rates of release of bound NADPH and NADP+ from their dIII sites.
These properties explain why forward and reverse transhydrogena-
tion reactions in dI2dIII1 complexes are slow, but the cyclic reaction is
fast [36]. The rapid rate of direct hydride transfer is reﬂected by the
close apposition of the C4 atoms of the two nicotinamide rings of, for
example, tetrahydro-NADH and NADP+ in crystal structures [19].
NADPH and NADP+ release from dIII in dI2dIII1 complexes is thoughtto be restricted as a result of the loop E “lid” being closed down over
the bound nucleotide in the occluded state [15], and see [59].
The present experiments show that the binding of nucleotides
(NADP+, NADPH and the special cases, NAD+, NADH) to the dIII site in
dI2dIII1 complexes is also very slow. The new data, and the results
described in previous work, are readily explained by the scheme for
nucleotide binding and release shown in Fig. 6. In this scheme,
isolated dI2dIII1 complexes, whether they are in the apo- or
nucleotide-bound forms, are maintained predominantly in the
occluded state: the equilibrium constant, K′, is small, and K‴ is large.
The slow rates of NADP+, NADPH, NAD+ and NADH binding seen in
theﬂuorescence experiments (Fig. 5), and of NADP+ andNADH binding
in the analysis of the cyclic and aberrant cyclic assays (Figs. 2 and 3), are
all similar. The observed nucleotide binding does not ﬁt to second
order reaction kinetics (see Results). In terms of the model, these
ﬁndings are explained by the notion that the rate-limiting step in
nucleotide binding to apo-dIII in dI2dIII1 complexes is the conversion
of the occluded to the open states, which is governed by k1; the true
second order rate constant k3 is expected to be large, and to give rise
to rapid rates of binding only to the open state. Thus, the kinetics of
the lag phase (Fig. 3), and of the ﬂuorescence change resulting from
nucleotide binding (Fig. 5), give the value of k1 (~0.03 s−1). In the
intact enzyme this is increased to at least the turnover number of the
enzyme (~50 s−1), and the step is a candidate for one whose rate is
modulated by remote interaction with H+ during translocation
through dII.
dI2dIII
k1 dI2dIII K'= k1 / k2
k
dI2dIII +   Nuc dI2dIII -Nuc        K'' = k3 / k4
2
k3
k4
dI2dIII -Nuc dI2dIII -Nuc         K'''= k 5 / k6
k5
k6
Fig. 6. Nucleotide binding to the dIII component of the dI2dIII1 complex. The dI2dIII1
complex can adopt either an occluded state (shown in italics) or an open state (shown in
bold). In isolated complexes, the occluded state ismore stable (K′ is small and K‴ is large).
Nucleotide (“Nuc”) binding to dIII can only take place when the complex is in the open
state. Binding of nucleotide to the dI component is not shown but it can occur in either the
open or the occluded states. Hydride-transfer reactions can only take place in the occluded
state. The subscript “1” is omitted from dIII in the dI2dIII1 complex for clarity.
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than from the wild-type protein (Table 1). However, the rates of
nucleotide binding to complexes of dI and dIII.R165A, from the kinetics
of the lag in cyclic and aberrant cyclic transhydrogenation, and from the
kinetics of ﬂuorescence changes, were not signiﬁcantly different from
those observed in complexes with wild-type dIII. It is therefore
concluded that the afﬁnity for NADP+ of the open state of dIII in the
complexes (Kd=1/K″ in Fig. 6) is decreased by themutation but that the
value of k1 is unaffected. The decreased afﬁnity is not unexpected
because, in crystal structures of wild-type dIII, Arg165 (together with
Lys164 and Ser166) participates in a network of H-bond interactions
with the 2′-phosphate of NADP+/NADPH [15,19,60]. The three amino
acid residues are located at the N-terminus of loop E; the unchanged k1
value indicates that the R165Amutation does not greatly affect the rate
of opening of loop E to expose the nucleotide-binding site during the
transition between the open and occluded states.
The somewhat unexpected ﬁnding that NADH/NAD+ (or, it was
thought, AcPdADH/AcPdAD+) can bind into the dIII component of
hybrid (R. rubrum/E. coli) dI2dIII1 complexes and support high rates of
an aberrant cyclic reaction [43], is conﬁrmed by the experiments
described in this report with complexes from the R. rubrum enzyme;
in fact, the reaction kinetics show that only NADH/NAD+ (and not
AcPdADH/AcPdAD+) are effective at the concentrations used. The
data from the reaction kinetics and ﬂuorescence experiments suggest
that the afﬁnities of dIII for nucleotides are in the order,
NADPHNNADP+≈NADHNNAD+NAcPdAD+. Structural differences
between the NADPH- and NADP+-bound forms of dIII are detected
as chemical shift changes in NMR experiments [61,62] but these
differences have not been identiﬁed in X-ray data at current
resolution [18,60]. It seems that, also with NAD+/NADH, the reduced
nucleotide has the higher afﬁnity for dIII. Weaker binding of NADH
than of NADPH (and of NAD+ than NADP+) is presumably a
consequence of the replacement of the 2′-phosphate group with a
hydroxyl, leading to a loss of some or all of the H-bonds with Lys164,
Arg165 and Ser168, to local structural re-organisation, and thus to a
decrease in binding energy. The still weaker binding of AcPdAD+ to
dIII is the result of the replacement of the carboxamide of the
nicotinamide ring with an acetyl group. Depending on species, the
NH2 of the NADP+ carboxamide makes potential H-bonds with either
or both of the peptide carbonyls of the highly conserved, Ala88 and
Val87 [14,15,19]. The weaker binding of AcPdAD+ may be a
consequence of the fact that its acetyl group is unable to make
equivalent H-bonds. Because of difﬁculties in interpreting the kinetics,
the conclusion that the decrease of afﬁnity for NADP+ appears to be
more pronounced than that for NADH in dIII.R165A (see Fig. 4) should
be treated with caution but it can be understood if, as expected,
binding with the latter nucleotide relies less on interactions with the
guanidinium group of Arg165.An interesting question remains as to the possibility that, in some
metabolic conditions in the cell, nucleotides might occupy the wrong
sites of transhydrogenase. Of course, the cyclic and aberrant cyclic
reactions of the enzyme are only observed experimentally with the
non-physiological nucleotide, AcPdAD+. The equivalents of the two
reactions with physiological nucleotides have no metabolic conse-
quence; neither results in any change in nucleotide redox state (both
entail the reduction of NAD+ by NADH), and neither leads to proton
translocation across the membrane. Moreover, the cyclic and aberrant
cyclic reactions would probably only take place at relatively low rates
in the living cell: in contrast to dI2dIII1 complexes, the occluded state
of the intact enzyme rapidly interconverts with the open state to
permit exchange of the dIII-bound nucleotides with those in the
solvent—and this breaks the cycling. Of possible metabolic signiﬁ-
cance is the ﬁnding that the speciﬁcity of the dIII site for NADP+/
NADPH relative to NAD+/NADH is not as great as was once thought.
The lack of information on speciﬁcity constants for nucleotides at this
site makes analysis difﬁcult. However, if we assume that dI is highly
speciﬁc for NAD+/NADH, which is supported experimentally [24,25],
then two situations may be considered. Firstly, if NADH binds to dIII
and NAD+ to dI, then hydride transfer (not resulting in any change in
overall nucleotide redox state) will lead to outward proton translo-
cation. Since there is no free energy available from this redox reaction,
it will only take place if proton transfer through transhydrogenase is
downhill, i.e. if the proton electrochemical potential inside the
bacterial cell is positive relative to that outside (ΔpN0)—perhaps an
unlikely situation under physiological conditions. Secondly, if NAD+
binds to dIII and NADH to dI, then hydride transfer (again not
resulting in any overall change in nucleotide redox state) will lead to
inward proton translocation; this will only take place if Δpb0. We
should expect a single proton to be translocated for each hydride-ion
equivalent transferred from NADH to NAD+, equivalent to the
experimentally determined, H+/H−=1, during AcPdAD+ reduction
by NADPH [63]. In this situation transhydrogenase would effectively
dissipate Δp and “uncouple”, for example, the respiratory chain
from ATP synthesis. Transhydrogenase would behave as an
outwardly directed proton diode gated by the redox states of the
nicotinamide nucleotides. The process could be metabolically
important if NAD+/NADH becomes predominantly oxidised, and if
the free concentrations of NADP+/NADPH are low. Our knowledge
of the redox states of the nicotinamide nucleotides in bacterial cells,
and even in the mitochondrial matrix of animal cells, is very
limited, and it is therefore very difﬁcult to assess whether such
conditions are ever met, and whether this slip reaction is likely to
impinge on metabolism. The alternative possibility, that NADP+/
NADPH concentrations are too high ever to allow NAD+/NADH
binding to dIII, and that transhydrogenase always behaves as
described by Eq. (1), cannot therefore be ruled out.
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